In a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...
Read MoreWhat type of stem cell transplant is most effective after early treatment failure in follicular lymphoma?
In a nutshell This study investigated the effectiveness of stem cell transplantation in follicular lymphoma patients who experienced early treatment failure after frontline chemoimmunotherapy. This study concluded that transplants using the patient's own stem cells or those from a matched sibling donor lead to better survival outcomes in these...
Read MoreRadiotherapy for relapsed or refractory diffuse large b-cell lymphoma
In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...
Read MoreLenalidomide and blood clots: low risk in CLL and NHL
In a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...
Read MoreImpact of severe side effects on outcomes of older patients with non-Hodgkin lymphoma
In a nutshell This study examined whether newer therapies for non-Hodgkin lymphoma (NHL) were associated with higher odds of negative side effects in older patients. The study concluded that NHL patients over age 65 experienced more serious side effects than younger patients, and these side effects were associated with worse outcomes. Some background...
Read MoreDoes G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?
In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...
Read MoreReviewing radiation therapy options for patients with relapsed or persistent DLBCL
In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...
Read MoreAlternating R-CHOP and R-cytarabine for transplant-ineligible MCL patients
In a nutshell This study investigated the safety and effectiveness of a chemotherapy regimen alternating R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-cytarabine (rituximab combined with cytarabine) for mantle cell lymphoma (MCL) patients ineligible for stem cell transplant (SCT). This study concluded that alternating...
Read MoreDoes prephase treatment help improve post-chemotherapy outcomes for newly diagnosed DLBCL patients?
In a nutshell This study investigated the outcomes of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients who received prephase treatment before chemotherapy. This study concluded that this treatment before chemotherapy improves symptoms and reduces chemotherapy-related side effects in these patients. Some background Diffuse large B-cell...
Read MoreHow effective and safe is ibrutinib compared to temsirolimus for relapsed or persistent mantle cell lymphoma?
In a nutshell This study compared the effectiveness and safety of ibrutinib (Imbruvica) versus temsirolimus (Torisel) in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib significantly improved survival outcomes compared to temsirolimus for these patients. Some background...
Read MoreIs rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?
In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...
Read More
